Abstract
Study Objectives Sleep disturbances and genetic variants have been identified as risk factors for Alzheimer’s disease. Our goal was to assess whether genome-wide polygenic risk scores (PRS) for AD associate with sleep phenotypes in young adults, decades before typical AD symptom onset.
Methods We computed whole-genome Polygenic Risk Scores (PRS) for AD and extensively phenotyped sleep under different sleep conditions, including baseline sleep, recovery sleep following sleep deprivation and extended sleep opportunity, in a carefully selected homogenous sample of healthy 363 young men (22.1 y ± 2.7) devoid of sleep and cognitive disorders.
Results AD PRS was associated with more slow wave energy, i.e. the cumulated power in the 0.5-4 Hz EEG band, a marker of sleep need, during habitual sleep and following sleep loss, and potentially with large slow wave sleep rebound following sleep deprivation. Furthermore, higher AD PRS was correlated with higher habitual daytime sleepiness.
Conclusions These results imply that sleep features may be associated with AD liability in young adults, when current AD biomarkers are typically negative, and the notion that quantifying sleep alterations may be useful in assessing the risk for developing AD.
Statement of Significance We show that the genetic liability for developing for Alzheimer’s disease (AD), as grasped over the entire genome using polygenic risk scores (PRS), is associated with sleep intensity and daytime sleepiness in healthy individuals devoid of sleep disorders and aged < 30 y, i.e. 30 to 60 years before typical onset of AD cognitive symptoms. Sleep features may be associated with AD liability in young adults, when current AD biomarkers are typically negative. The findings reinforce the notion that quantifying sleep alterations may be useful in assessing the risk for developing AD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
P.G., M.V., C.S., F.C., C.P. and G.V. are supported by the Fonds de la Recherche Scientifique - FNRS-Belgium. The study was supported by the Wallonia-Brussels Federation (Actions de Recherche Concertees - ARC - 09/14-03), WELBIO/Walloon Excellence in Life Sciences and Biotechnology Grant (WELBIO-CR-2010-06E), FNRS-Belgium (FRS-FNRS, F.4513.17 & T.0242.19 & 3.4516.11), University of Liege (ULiege), Fondation Simone et Pierre Clerdent, European Regional Development Fund (Radiomed project), Fonds Leon Fredericq. DJD is supported by the UK Dementia Research Institute (DRI).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The authors declare that the data supporting the findings of this study are available from the corresponding author upon request.
